相关实验视频
Updated: Jun 30, 2025
08:39
Murine Colitis Modeling using Dextran Sulfate Sodium DSS
Published on: January 19, 2010
49.9K
ресвератрол通过对小鼠肠道微生物群的作用来改善DSS诱导的性结肠炎
Bing Yu1, Ying Wang2, Zekai Tan2
1School of Materials and Energy, Guangdong University of Technology, Guangzhou, 510006, China.
Inflammopharmacology
|March 16, 2024
概括
Resveratrol (RSV) 通过减少炎症和改善结肠长度,有效地减少了小鼠的性结肠炎 (UC) 严重程度. 这项研究证明了RSV.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 微生物学 微生物学
背景情况:
- 性结肠炎 (UC) 是一种慢性免疫疾病,通常需要长期服用药物.
- 肠道微生物群在宿主健康中起着至关重要的作用,影响免疫反应.
- 复星 (RSV) 在UC的治疗潜力,特别是它对肠道微生物群的影响,仍未得到充分研究.
研究的目的:
- 在硫酸 (DSS) 诱导的性结肠炎 (UC) 的小鼠模型中研究复星 (RSV) 的抗炎作用.
- 探索RSV如何调节肠道微生物群的组成和多样性,在UC的背景下.
- 评估RSV对关键炎症标志物和结肠组织完整性的影响.
主要方法:
- 在小鼠中诱导大肠炎使用硫酸 (DSS).
- 给DSS治疗的小鼠服用不同剂量的复星 (RSV).
- 评估结肠长度,组织学分数 (H&E染色),以及通过免疫组织化学对COX-2和TNF-α的表达.
- 使用α-多样性指数,sobs指数,稀缺曲线和PCoA.分析肠道微生物群的组成和多样性.
主要成果:
- 高剂量的RSV (40 mg/kg) 显著减轻了UC的严重程度,并减少了结肠缩短.
- 与仅服用DSS的组相比,RSV治疗导致结肠COX-2和TNF-α水平显著下降.
- 给予RSV改变了肠道微生物群的组成,增加了某些物种的相对丰度,增强了微生物的多样性和统一性.
结论:
- 复星在小鼠中表现出显著的保护作用,防止DSS诱导的性结肠炎.
- RSV通过减少结肠炎症和调节肠道微生物群来发挥其治疗效益.
- 这些发现表明RSV是治疗性结肠炎的潜在治疗剂.
更多相关视频
08:53Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
827
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
12.3K
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
139
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
139
01:17Drugs for Treatment of Diarrhea-Predominant IBS
167
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
167